Adult and Near-Adult Height in Patients with Severe Insulin-Like Growth Factor-I Deficiency after Long-Term Therapy with Recombinant Human Insulin-Like Growth Factor-I

Hormone Research in Paediatrics

Volumn 80, Issue 1, 2013, Pages 47-56

  Backeljauw, Philippe F ^a   Kuntze, Joyce ^b   Frane, James ^c   Calikoglu, Ali S ^d   Chernausek, Steven D ^e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Clinical Consultant   (United States)

^c Statistical Consultant   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Growth; Insulin like growth factor I therapy; Severe insulin like growth factor I deficiency

Indexed keywords

ALBUMIN; AMINOTRANSFERASE; BILIRUBIN; CREATININE; GONADORELIN DERIVATIVE; GOSERELIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; LACTATE DEHYDROGENASE; LEUPRORELIN; NITROGEN; PROTEIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; THYROTROPIN; TRIPTORELIN; UREA;

ARTICLE; BODY COMPOSITION; BODY FAT; BODY GROWTH; BODY HEIGHT; BODY MASS; BONE MASS; BONE MATURATION; BONE MINERALIZATION; CATCH UP GROWTH; CHILD; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FACE GROWTH; FEMALE; GROWTH CURVE; GROWTH HORMONE DEFICIENCY; HEART FUNCTION; HORMONE BLOOD LEVEL; HUMAN; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; KIDNEY SIZE; LARON SYNDROME; LONG TERM CARE; MALE; OPEN STUDY; ORGAN GROWTH; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBERTY; SCHOOL CHILD; SOMATOMEDIN C DEFICIENCY; SPLEEN SIZE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; CHILD GROWTH; INSULIN LIKE GROWTH FACTOR 1 DEFICIENCY; PROTEIN DEFICIENCY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84880407955     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000351958     Document Type: Article

References (38)

1. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood, LE: Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92: 902-910.
2. Backeljauw PF: Diagnosis and management of primary insulin-like growth factor-I deficiency: current perspectives and clinical update. Pediatr Endocrinol Rev 2010; 7(suppl 1):154-171.
3. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A: Roles of growth hormone and insulin-like growth factor-1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.
4. Rosenfeld RG, Hwa V: New molecular mechanisms of GH resistance. Eur J Endocrinol 2004; 151(suppl 1):S11-S15.
5. Wit JM: Diagnosis and management of disorders of IGF-I synthesis and action. Pediatr Endocrinol Rev 2011; 9(suppl 1):538-540.
6. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P: Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999; 51: 128-134.
7. Backeljauw PF, Underwood LE: Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001; 86: 1504-1510.
8. Klinger B, Laron Z: Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-158.
9. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG: Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
10. Roche AF, Chulmea CW, Thissen D: Assessing the Skeletal Maturity of the Hand-Wrist: FELS Method. Springfield, Thomas, 1988.
11. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL: CDC growth charts: United States. Adv Data 2000;314:1-27.
12. Laron Z, Lilos P, Klinger B: Growth curves for Laron syndrome. Arch Dis Child 1993; 68: 768-770.
13. Rosenberg HK, Markowitz RI, Kolberg A, Park C, Hubbard A, Bellah RD: Normal splenic size in infants and children; sonographic measurements. Am J Roentgenol 1991; 157: 119-121.
14. Concolino D, Muzzi G, Sestito S, Vega G, Bonapace G, Strisciuglio P: Long-term treatment with recombinant insulin-like growth factor 1 (IGF-1) in a child with IGF-1 gene mutation. Eur J Pediatr 2010; 169: 245-247.
15. Heinrichs C, Vis HL, Bergmann P, Milton P, Bourguignon JP: Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin Endocrinol (Oxf) 1993; 38: 647-651.
16. Zucchini S, Scarano E, Baldazzi L, Mazzanti L, Pirazzoli P, Cacciari E: Final height in a patient with Laron syndrome after long-term therapy with rhIGF-I and short-term therapy with LHRH analogue and oxandrolone during puberty. J Endocrinol Invest 2005; 28: 274-279.
17. Vance ML, Mauras N: Growth hormone therapy in adults and children. N Engl J Med 1999; 341: 1206-1216.
18. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D: Liver-specific IGF-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001; 50: 1110-1118.
19. Sjögren K, Liu J, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith K, Torn ell J, Isaksson OGP, Jansson JO, Ohlsson C: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999; 96: 7088-7092.
20. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A: Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.
21. Pertzelan A, Lazar L, Klinger B, Laron Z: Puberty in 15 patients with Laron syndrome: a longitudinal study; in Laron Z, Parks JS (eds): Lessons from Laron syndrome 1966-1992: a model of GH and IGF-I action and interaction. Pediatr Adolesc Endocrinol 1993; 24: 27-33.
22. Laron Z, Klinger B: Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998; 138: 176-180.
23. Laron Z: Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2006; 89: 1031-1044.
24. Darendeliler F, Hindmarsh PC, Preece MA, Cox L, Brook CGD: Growth hormone increases rate of pubertal maturation. Act Endocrinol (Copenh) 1990; 122: 414-416.
25. Aynsley-Green A, Zachmann M, Prader A: Interrelation of the therapeutic effects of growth hormone and testosterone on growth in hypopituitarism. J Pediatr 1976; 89: 992-999.
26. Zapf J, Scheele E, Wald Vogel M, Sand I, Frisch ER: Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 1981; 113: 605-609.
27. Blinder J, Landlady A, Enfold P, Earner P: Studies of acute effects of insulin-like growth factors I and II in human fat cells. J Clin Endocrinol Metab 1987; 65: 732-737.
28. LeRoith D, Yakar S: Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007; 3: 302-310.
29. Guler HP, Zapf J, Scheiwiller E, Froesch ER: Recombinant human insulin-like growth factor-I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 1988; 85: 4889-4893.
30. Noto R, Maneatis T, Frane J, Alexander K, Lippe B, Davis DA: Intracranial hypertension in pediatric patients treated with recombinant human growth hormone: data from 25 years of Genentech National Cooperative Growth Study. J Pediatr Endocrinol Metab 2011; 24: 627-631.
31. Lordereau-Richard I, Roger M, Chaussain JL: Transient bilateral papilledema in 10-yearold boy treated with recombinant insulin-like growth factor I for growth hormone receptor deficiency. Acta Paediatr Suppl 1994; 399: 152.
32. Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM: Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab 2010; 95: 611-619.
33. Johansson JO, Larson G, Anderson M, et al: Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995; 61: 57-66.
34. Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z: Development of hyperandrogenism during treatment with insulin-like growth factor-I in female patients with Laron syndrome. Clin Endocrinol (Oxf) 1998; 48: 81-87.
35. Leonard J, Samuels M, Cotterill AM, Savage MO: Effects of recombinant insulin-like growth factor-I on craniofacial morphology in growth hormone insensitivity. Acta Paediatr Suppl 1994; 399: 140-141.
36. Backeljauw PF, Kissoondial A, Underwood LE, Simmons KE: Effects of 4-years treatment with recombinant human insulin-like growth factor I (RhIGF-I) on craniofacial growth in children with growth hormone insensitivity syndrome (GHIS). Horm Res 1997;48:(suppl 2):40.
37. David A, Hwa V, Metherell LA, et al: Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 2011; 32:472-497.
38. Han BK, Babcock DS: Sonographic measurements and appearance of normal kidneys in children. AJR Am J Roentgenol 1985; 145: 611-616.